CVN417 is an orally active alpha6 subunit-containing nAChR antagonist, modulating phasic dopaminergic neurotransmission in an impulse-dependent manner. CVN417 inhibits Ca(2+) effluents mediated by nAChR subunits with IC50s of 0.086 µM (alpha6), 2.56 µM (alpha3) and 0.657 µM (alpha4), respectively. CVN417 attenuates resting tremor in Rodent models, displays the potential to improve movement dysfunction, in conditions such as Parkinsons disease[1].
Molekulargewicht:
362.85
CAS Nummer:
[2919851-73-1]
Formel:
C18H23ClN4O2
Target-Kategorie:
nAChR
Anwendungsbeschreibung:
Reference compound
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
